There are two RA positions open in Pediatric Oncology at Dana Farber. Dr. Birgit Knoechel writes, “The overarching goal of my lab and the Lohr lab is to study the biology of therapeutic resistance in cancer with a particular focus on genomic and epigenetic aberrations. We use single cell/low input genomics, epigenomics and other single cell technology to define dynamic changes in tumor model systems and primary patient samples with a disease focus on hematologic malignancies and sarcoma. We also use a wide variety of tools to study underlying mechanisms, which span the entire spectrum from biochemistry, functional perturbation to in vivo mouse models.”

Click on the titles to learn how to apply.

RA Epigenetics – The Dana-Farber Cancer Institute is looking for an exceptional candidate for a unique Research Associate position. This position affords the exciting opportunity to be part of a research effort at Dana-Farber Cancer Institute aiming to delineate epigenomic aberrations in cancer and discover novel therapeutic targets. The candidate will assist in the development of cancer models from primary human tumors and human cell lines that represent different cellular lineages and drug-resistant states. He/she will use modern next generation sequencing techniques to characterize the chromatin state of these tumors and modern functional perturbation techniques including lentiviral knockdown and CRISPR/Cas9 genome editing tools. He/she will test the model systems in immuno-compromised mice for their ability to form tumors and to test for drug responses. He/she will be part of a multi-disciplinary team that evaluates new technologies and approaches to discover and validate novel systemic cancer biology.

RA Genomics – Dana-Farber Cancer Institute is looking for an exceptional candidate for a unique Research Associate position. This position affords the exciting opportunity to be part of a research effort at Dana-Farber Cancer Institute aiming to delineate genomic aberrations in cancer biology and discover novel therapeutic targets. He/she will use modern next generation sequencing techniques to characterize genomic aberrations and modern functional perturbation techniques including CRISPR/Cas9 and other genome editing tools. He/she will use various model systems to test for drug responses and determine mechanisms of resistance to drugs, including novel immunotherapies. He/she will be part of a multi-disciplinary team that evaluates new technologies and approaches to discover and validate novel systemic cancer biology.